Shionogi & Co., Ltd. announced that it will acquire US-based IntraBio for $2 billion. The company aims to expand its rare neurological disease business centered on AQNEURSA.
Shionogi & Co., Ltd. agreed to acquire US-based IntraBio for $2 billion (approximately ¥315.6 billion). IntraBio will become a wholly owned subsidiary of Shionogi Inc., and the acquisition will be carried out by Shionogi's US group.
The acquisition will bring in IntraBio's development assets for small-molecule drugs for rare diseases and accelerate the rollout of treatments centered on AQNEURSA (generic name: levacetylleucine). AQNEURSA has been approved in Europe and the United States to treat neurological symptoms associated with Niemann-Pick disease type C, and sales have begun in the United States.
Shionogi & Co., Ltd. is pursuing the global rollout of the ALS treatment Radicava and plans to accelerate research and development in the rare disease field by acquiring IntraBio's personnel and expertise.
Following the acquisition, Shionogi will obtain worldwide rights to AQNEURSA and related compounds. IntraBio is a biopharmaceutical company focused on rare diseases, with strengths in developing small-molecule drugs targeting lysosomal function and intracellular calcium signaling.